NRx Pharmaceuticals Earnings Call Transcripts
Fiscal Year 2026
-
Q1 2026 saw major regulatory and commercial progress, including advancing preservative-free ketamine toward FDA approval, expanding clinical operations, and acquiring new CNS assets. Net loss dropped 74% year-over-year, and $7 million was raised post-quarter.
-
The meeting covered board elections, approval of incentive plan amendments, auditor ratification, and executive compensation, all of which passed by majority vote. 2025 marked the first year of revenue-generating clinical operations, with optimism for drug approval and continued growth.
Fiscal Year 2025
-
2025 saw reduced losses, new revenue from clinic operations, and major progress toward drug approvals for KETAFREE, NRX-100, and NRX-101. Cash resources and cost controls are expected to support operations through 2026, with profitability targeted by year-end.
-
FDA accepted the ANDA for a preservative-free ketamine, targeting a July 2026 review completion. NRx-101, combined with TMS, shows strong efficacy in depression and suicidality, with a phase 3 trial planned and expanded access underway.
-
Q3 2025 saw first-ever revenue from clinic acquisitions, expanded drug pipelines, and key regulatory progress, including fast-track FDA designations. Losses increased due to R&D and integration costs, but cash reserves are sufficient for operations through mid-2026.
-
Plans to generate revenue from three lead programs, including IV ketamine and a novel oral therapy, are underway. Clinical data support ketamine's efficacy in suicidality and PTSD, while regulatory fast-tracking and federal focus on mental health may accelerate approval.
-
The event highlighted the advancement of novel neuropsychiatric treatments, including preservative-free ketamine and a new oral therapy for bipolar depression, alongside the rollout of a national clinic network targeting major unmet needs. Hope Therapeutics aims for $100 million revenue and profitability by end of 2025.
-
Q2 2025 saw a 47% reduction in operating loss, strengthened balance sheet, and progress on three drug approval applications. Regulatory milestones include expanded FDA fast-track for NRX-100 and a citizen petition that could boost market share.
-
Advanced regulatory filings for NRx-100 and NRx-101, expanded HOPE Therapeutics clinic network, and reduced operating expenses. Q1 2025 net loss improved to $5.5M, with profitability targeted by year-end 2025 and significant non-dilutive financing secured.
Fiscal Year 2024
-
Loss from operations fell 33.5% to $18.5M in 2024, driven by lower R&D and admin costs. NDA filings for NRX-100 and NRX-101 are advancing, with a $300M+ licensing term sheet for NRX-100 and plans to acquire 20 profitable clinics to drive 2025 profitability.
-
Q3 2024 saw a 74% reduction in net loss and major progress toward NDA filings for NRx-100 and NRx-101, with profitability forecast for 2025. Hope Therapeutics is set to generate revenue by year-end, supported by new financing and strategic clinic acquisitions.
-
The presentation outlined a strategy to address suicidality through innovative drug development and a national clinic network, targeting major unmet needs in mental health. NDA filings for IV ketamine and an oral bipolar depression therapy are planned this year, with rapid clinic expansion underway.
-
Q2 2024 saw reduced net loss, major cost cuts, and new financing to support two NDA filings for NRX-100 and NRX-101, with commercial launches targeted for 2025. Hope Therapeutics' clinic network and a leadership transition are underway to drive future growth.
-
NRX-101 has shown efficacy in reducing suicidality and akathisia in bipolar depression, with plans for accelerated FDA approval and broader trials. Strategic partnerships, a new ketamine formulation, and the HOPE Therapeutics spin-out position the company for significant growth and cash flow in 2025.